Skip to content
Clinical Trials – home
SpainBack to Spain

Clinical trials in Santander – page 37

599 clinical trials in Santander, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Santander at a glance
599
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

599 trials in Santander

Open in trial search

Study of Belumosudil and Prednisone for Patients Aged 12 and Older with Newly Diagnosed Chronic Graft Versus Host Disease

Registered drug
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study of Niraparib and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Plasma cell myeloma

Not recruiting

Study Comparing Talquetamab, Pomalidomide, and Teclistamab for Patients with Relapsed or Refractory Myeloma After 1 to 4 Prior Treatments

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Gastric cancer

Not recruiting

Study of Bemarituzumab with Chemotherapy and Nivolumab in Untreated Advanced Gastric and Gastroesophageal Junction Cancer Patients with FGFR2b Overexpression

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bemarituzumab
  • Sponsor:Amgen Inc.

Bladder cancer

Not recruiting

Study of Sacituzumab Govitecan, Zimberelimab, and Domvanalimab for Patients with Muscle Invasive Bladder Cancer Ineligible for Cisplatin Chemotherapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Domvanalimab
  • Sponsor:Fundacion Para El Progreso De La Oncologia En Cantabria

Plasma cell myeloma

Not recruiting

Study on Talquetamab and Tocilizumab for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Talquetamab
  • Sponsor:Janssen Cilag International

Study on the Effectiveness of Autogene Cevumeran in Patients with ctDNA Positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Autogene Cevumeran
  • Sponsor:BioNTech SE

Bladder cancer

Not recruiting

Study on the Effectiveness and Safety of Durvalumab with Gemcitabine and Cisplatin for Patients with Muscle-Invasive Bladder Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:AstraZeneca AB

Study on the Use of Human Normal Immunoglobulin for Preventing Infections in Patients with Chronic Lymphocytic Leukemia and Secondary Immunodeficiency

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Octapharma Pharmazeutika Produktionsgesellschaft mbH

Gastric cancer

Not recruiting

Study of ALX148 with Trastuzumab, Ramucirumab, and Paclitaxel for Patients with Advanced Gastric or Gastroesophageal Junction Cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel
  • Sponsor:Alx Oncology Holdings Inc.

Study of Nivolumab and Ipilimumab for Patients with Advanced Liver Cancer (Hepatocellular Carcinoma) as First-Line Treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Chronic hepatitis B

Not recruiting

Long-term Study on Treatment Response in Chronic Hepatitis B Patients Using Bepirovirsen

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bepirovirsen
  • Sponsor:Glaxosmithkline Research & Development Limited

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Santander

What the registry says about research in the country

01 Oncology Research

Groundbreaking trials focusing on metastatic colorectal cancer, mantle cell lymphoma, and gastrointestinal cancers. Studies evaluate novel combination therapies and targeted treatments for improved patient outcomes.

  • Colorectal Cancer Treatment Innovations
  • Lymphoma Therapy Advances
  • Gastric Cancer Interventions

Multiple studies exploring new therapeutic approaches for various cancer types, including melanoma and lung cancer.

02 Respiratory Medicine

Clinical trials investigating treatments for chronic rhinosinusitis and uncontrolled asthma. Research focuses on developing innovative therapies and improving patient quality of life.

  • Asthma Management
  • Nasal Polyps Treatment
  • Respiratory Disease Control

Studies evaluate both established and novel therapeutic approaches for respiratory conditions.

03 Autoimmune Disorders

Innovative research examining treatments for psoriatic arthritis and Sjögren's disease. Trials focus on evaluating new biological therapies and their effectiveness in managing symptoms.

  • Arthritis Treatment Solutions
  • Autoimmune Disease Management
  • Biological Therapy Assessment

Comprehensive studies targeting various manifestations of autoimmune conditions.

04 Neurological Studies

Research investigating treatments for Alzheimer's disease and its connection with Down syndrome. Studies also include trials for multiple sclerosis and related neurological conditions.

  • Alzheimer's Disease Research
  • Multiple Sclerosis Treatments
  • Neurological Disease Management

Focused on developing effective treatments for complex neurological disorders.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.